Global Tinea Corporis Market Overview
The Tinea Corporis Market Size was valued at USD 14.24 Billion in 2023. The Global Tinea Corporis industry is projected to grow from USD 14.38 Billion in 2024 to USD 20.17 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.52% during the forecast period (2024 - 2032).
Tinea corporis is a fungal infection that is caused by tinea rubrum, trichophyton mentagrophytes and epidermophyton floccosum fungi. This fungal infection mainly occurs in humid climatic condition. It is also known as ringworm infection. Tinea corporis infection occurs mostly on arms, legs or can also occur on different parts of body. Tinea corporis is contagious infection which can spread from one person to other hence it is important not to share towel, flannels, bathmats with another person.
Tinea Corporis Market Trends
The tinea corporis market is expected to see the growth in upcoming year due to entry of new drug product in market for treatment. Many key players in market are engaged in development of new drug product for tinea corporis treatment. The prevalence of tinea infection is higher in humid climatic condition. Increasing incidences of fungal diseases and increasing prevalence of various skin disorders are some of the key factors responsible for the market growth. Various other factors such as increasing awareness regarding skin infection, new drug development, are also driving the global tinea corporis market.
However certain factors that can hamper the growth of this market in near future are lack of awareness regarding fungal disease, adverse side effect due to antifungal drugs and alternative treatment plans.
Tinea Corporis Market Segment Insights
Global tinea corporis market is segmented into drug type, diagnosis, treatment and end-users. Tinea corporis market on basis of drug types is segmented into antifungals, steroids and anti-infective combinations.
Based on diagnosis tinea corporis market is segmented into physical exam, imaging tests. Imaging test is further sub-segmented into wood lamp (black light) examination, microscopy using potassium hydroxide (KOH), fungal culture, skin biopsy and others.
Based on treatment tinea corporis market is segmented into antifungal shampoos, antifungal creams, drugs and others. On basis of end-user market is further segmented into hospital pharmacies, drug stores, online pharmacies, dermatology hospitals, medical research centres, academic institutes others.\
Tinea Corporis Market Drug Type Insights
- Antifungals
- Steroids
- Anti-Infective Combinations
Tinea Corporis Diagnosis Insights
- Physical Exam
- Imaging Tests
- Wood lamp (black light) examination
- Microscopy using potassium hydroxide (KOH)
- Fungal culture
- Skin biopsy
- Others
Tinea Corporis Treatment Insights
- Antifungal shampoos
- Antifungal creams
- Drugs
- Others
Tinea Corporis End-Users Insights
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
- Dermatology hospitals
- Others
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The tinea corporis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. US account for the largest share of the tinea corporis market.
The European tinea corporis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The tinea corporis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The tinea corporis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Tinea Corporis Regional Insights
Geographically, the America holds the highest market share for tinea corporis market and the reason being many market players are engaged in development of new drug product innovation, and as this infection is more prone to humid climatic condition there is an increasing prevalence of fungal infection in this region. Whereas increasing awareness of fungal disease and rising healthcare expenditure by the government are some of the factors responsible for growth of market in this region
Europe is expected to be the second largest market in the globe owing to the increasing aging population, increasing prevalence of fungal infection, focus on aesthetic appearance, increasing research base. Whereas rise in susceptible immune compromised patient population is responsible for market growth in this region.
Asia-Pacific is anticipated to be the fastest growing market owing to the growing prevalence of fungal infection, changing lifestyle, increase in population, increasing healthcare expenditure by government are some of the factor responsible for market growth in this region.
Tinea Corporis Market Key players
Some of the key players in the global tinea corporis market are
- Taro Pharmaceuticals., Inc.
- Teva Pharmaceuticals, Inc.
- Glenmark Pharmaceuticals Inc
- Breckenridge Pharmaceutical, Inc.
- NorthStar Rx LLd
- Aurobindo Pharma Limited
- Camber Pharmaceuticals, Inc.
- AvKare, Inc.
- Novartis AG
- Sebela Pharmaceuticals, Inc.
- Bayer AG
- Blueberry Therapeutics Ltd
- Perrigo Company
Tinea Corporis Regional Outlook
- Americas
- North America
- South America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Republic of Korea
- Rest of Asia Pacific
- The Middle East & Africa
Intended Audience
-
- Manufacturers and Suppliers
- Hospitals and Clinics
- Laboratories and Associations
- Research Institutes
- Dermatology Clinics
Report Attribute/Metric
|
Details
|
  Market Size 2032
|
 USD 20.17 Billion
|
  CAGR
|
  3.52% (2024-2032)
|
  Base Year
|
  2021
|
  Forecast Period
|
 2024-2032
|
  Historical Data
|
  2020
|
  Forecast Units
|
  Value (USD Billion)
|
  Report Coverage
|
  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
  Segments Covered
|
  Drug Type, Diagnosis, Treatment and End-Users
|
  Geographies Covered
|
  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
  Key Vendors
|
  Taro Pharmaceuticals., Inc., Teva Pharmaceuticals, Inc., Glenmark Pharmaceuticals Inc, Breckenridge Pharmaceutical, Inc., NorthStar Rx LLC, Aurobindo Pharma Limited, and Camber Pharmaceuticals, Inc., AvKare, Inc., Novartis AG, Sebela Pharmaceuticals, Inc., Bayer AG, Blueberry Therapeutics Ltd, Perrigo Company.
|
  Key Market Opportunities
|
  Entry of new drug product in market for treatment.
|
  Key Market Drivers
|
· Increasing incidences of fungal diseases and increasing prevalence of various skin disorders
· Increasing awareness regarding skin infection, new drug development
|
Tinea Corporis Market Highlights: